Indian pharma major Lupin Limited (Lupin) and Pharmacosmos have announced their launch of Monofer, an innovative iron isomaltoside formulation for the treatment of iron deficiency. Monofer will be marketed in India under the brand names "ISOFER" and "JILAZO".
Lupin has acquired the exclusive rights to market, distribute and sell iron isomaltoside in India, and will promote the two brands through its own sales force across the country.
The Haematinics* market in India is currently worth around 290 million USD and is growing at 11%. Out of this, the iron injectable market size is valued at 46 million USD with growth of 17% (IMS MAT AUG 2016).
"The launch of Isofer and Jilazo (Monofer) in India is a significant achievement and we are very happy to launch with such a strong partner such as Lupin. With this introduction in India, even more patients suffering from iron deficiency will have access to our intravenous iron therapy offering iron correction in one visit" says Michael Ryde, Vice President, Pharmacosmos.
*Substances that increase the amount of haemoglobin in the blood
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
The Company is a significant player in the Cardiovascular, Diabetologic, Asthmatic, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Monofer® (10% iron isomaltoside 1000) is an iron-carbohydrate complex for intravenous administration. Monofer® is already marketed in more than 30 countries, primarily in Europe, for the treatment of iron deficiency anaemia.
Monofer® is under development in the rest of the world, including North America and Japan. Monofer® is manufactured by Pharmacosmos, Denmark.
Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.
Pharmacosmos has subsidiaries in US, UK, Ireland, Germany, Sweden and Norway and its products are marketed in more than 80 countries around the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.
You are now leaving Pharmacosmos.com. The website you are about to visit is is a Pharmacosmos subsidary. Do you want to proceed?